AJTMH ASTMH MEMBERSHIP INFORMATION: astmh@astmh.org
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Am. J. Trop. Med. Hyg., 77(4), 2007, pp. 612-616
Copyright © 2007 by The American Society of Tropical Medicine and Hygiene

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rulisa, S.
Right arrow Articles by Ndayisaba, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rulisa, S.
Right arrow Articles by Ndayisaba, G.
Related Collections
Right arrow Malaria

Comparison of Different Artemisinin-based Combinations for the Treatment of Plasmodium falciparum Malaria in Children in Kigali, Rwanda, an Area of Resistance to Sulfadoxine-Pyrimethamine: Artesunate Plus Sulfadoxine/Pyrimethamine versus Artesunate Plus Sulfamethoxypyrazine/Pyrimethamine

Stephen Rulisa*, Jean Philip Gatarayiha, Tharcisse Kabarisa, AND Gill Ndayisaba
Central University Hospital of Kigali, Kigali, Rwanda; Rwanda National Institute of Statistics, Kigali, Rwanda; Kicukiro Health Center, Kigali, Rwanda; Lux Development Kigali, Rwanda

In view of the changing policy towards artemisinin-based combination therapies (ACTs), the efficacy, tolerance, and degree of re-infection of two ACTs were investigated: artesunate plus sulfadoxine/pyrimethamine (As + SP) and AS plus sulfamethoxypyrazine/pyrimethamine (As + SMP). One hundred three children were assigned to receive As + SP and 109 to receive As + SMP. In spite of the high incidence of resistance to SP, As + SP showed satisfactory results consistent with recent recommendations for ACTs (adequate clinical and parasitologic response on day 28 [ACPR] ≥ 90%), but results with As + SMP fulfilled the most stringent criteria (ACPR ≥ 95%). The absence of side effects and the low price of these drugs make them it worth to reconsider national therapies in favor of either of these two drug combinations.

Received August 23, 2006. Accepted for publication June 24, 2007.

Acknowledgments: We are grateful to all persons who participated in this study, the staff at the three sites for assistance, and Dr. A. Djimdé (Malaria Research and Training Centre, Bamako, Mali), for technical assistance in the analysis of the PCR samples.

Financial support: This study was supported by a grant from Dafra Pharma NV to Stephen Rulisa.

* Address correspondence to Stephen Rulisa, Central University Hospital of Kigali, BP 655 Kigali, Rwanda. E-mail: stevenruse{at}yahoo.com

Authors’ addresses: Stephen Rulisa, Central University Hospital of Kigali, BP 655 Kigali, Rwanda, E-mail: stevenruse{at}yahoo.com. Jean Philip Gatarayiha, National Institute of Statistics, BP 6139, Kigali, Rwanda, E-mail: gatarayihajp{at}hotmail.com. Tharcisse Kabarisa, Kicukiro Health Center, BP 2308 Kigali, Rwanda. Gill Ndayisaba, Lux Development , BP 3503 Kigali , Rwanda , E-mail : ndayisaba{at}gmail.com.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2007 by the American Society of Tropical Medicine and Hygiene.